Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
The purpose of this study is to evaluate the efficacy and safety of a single cardiac catheterization involving transendocardial delivery of allogeneic cells in improving clinical outcomes, preventing cardiac remodeling, and increasing exercise capacity in patients with chronic heart failure due to LV systolic dysfunction who have received optimal medical therapy.
Who may be Eligible
Patients with chronic heart failure (HF) due to left ventricular (LV) systolic dysfunction of either ischemic or non-ischemic etiology are eligible for enrollment, provided they meet all additional entry criteria. Additional entry criteria include, but are not limited to, age between 18-80 years of age, on stable doses of heart failure medical therapies, and is not a candidate for either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).